In the issue of March 2021, Lenschow et al. reported the case of a 46-year-old woman with recurrent, programmed death-ligand-1 (PD-L1) negative, tumor mutational burden (TMB)-high parathyroid carcinoma (PC), who showed stable disease as her best response on imaging, and a three-fold drop in PTH after treatment with intravenous pembrolizumab. Given the remarkable results obtained by Lenschow et al. with the anti-PD-1 agent pembrolizumab in the above-mentioned case, we performed an extensive search for possible further relevant data sources, including a) full published articles in international online databases (PubMed, Web of Science, Scopus, and Embase); b) preliminary reports in selected international meeting abstract repositories (American Society of Clinical Oncology, ASCO; European Neuroendocrine Tumor Society, ENET; European Society for Medical Oncology, ESMO); c) registered clinical trials in the U.S. National Institutes of Health registry of clinical trials (http://clinicaltrials.gov) and in any primary register of the WHO International Clinical Trials Registry Platform (ICTRP).

Commentary: case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management / Fanciulli, G.; Di Molfetta, S.; Dotto, A.; Florio, T.; Feola, T.; Colao, A.; Faggiano, A.; Nike, Group; Manuela, Albertelli; Barbara, Altieri; Luigi, Barrea; Filomena, Bottiglieri; Severo, Campione; Federica de Cicco, ; Alessandra, Dicitore; Diego, Ferone; Francesco, Ferraù; Erika, Grossrubatscher; Marco, Gallo; Giannetta, Elisa; Federica, Grillo; Elia, Guadagno; Valentina, Guarnotta; Isidori, Andrea M.; Andrea, Lania; Andrea, Lenzi; Fabio Lo Calzo, ; Pasquale, Malandrino; Erika, Messina; Roberta, Modica; Giovanna, Muscogiuri; Genoveffa, Pizza; Riccardo, Pofi; Puliani, Giulia; Carmen, Rainone; Paola, Razzore; Laura, Rizza; Manila, Rubino; Rosa Maria Ruggieri, ; Emilia, Sbardella; Franz, Sesti; Mary Anna Venneri, ; Giovanni, Vitale; Maria Chiara, Zatelli.. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - 12:(2021), p. 700806. [10.3389/fendo.2021.700806]

Commentary: case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management

Fanciulli G.;Feola T.;Faggiano A.;Elisa Giannetta;Andrea M. Isidori;Giulia Puliani;Franz Sesti;Mary Anna Venneri;
2021

Abstract

In the issue of March 2021, Lenschow et al. reported the case of a 46-year-old woman with recurrent, programmed death-ligand-1 (PD-L1) negative, tumor mutational burden (TMB)-high parathyroid carcinoma (PC), who showed stable disease as her best response on imaging, and a three-fold drop in PTH after treatment with intravenous pembrolizumab. Given the remarkable results obtained by Lenschow et al. with the anti-PD-1 agent pembrolizumab in the above-mentioned case, we performed an extensive search for possible further relevant data sources, including a) full published articles in international online databases (PubMed, Web of Science, Scopus, and Embase); b) preliminary reports in selected international meeting abstract repositories (American Society of Clinical Oncology, ASCO; European Neuroendocrine Tumor Society, ENET; European Society for Medical Oncology, ESMO); c) registered clinical trials in the U.S. National Institutes of Health registry of clinical trials (http://clinicaltrials.gov) and in any primary register of the WHO International Clinical Trials Registry Platform (ICTRP).
2021
immune checkpoint inhibitors; ipilimumab; nivolumab; parathyroid carcinoma; pembrolizumab; humans; lymph nodes; lymphatic metastasis; nivolumab; antineoplastic agents, immunological; parathyroid neoplasms
01 Pubblicazione su rivista::01b Commento, Erratum, Replica e simili
Commentary: case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management / Fanciulli, G.; Di Molfetta, S.; Dotto, A.; Florio, T.; Feola, T.; Colao, A.; Faggiano, A.; Nike, Group; Manuela, Albertelli; Barbara, Altieri; Luigi, Barrea; Filomena, Bottiglieri; Severo, Campione; Federica de Cicco, ; Alessandra, Dicitore; Diego, Ferone; Francesco, Ferraù; Erika, Grossrubatscher; Marco, Gallo; Giannetta, Elisa; Federica, Grillo; Elia, Guadagno; Valentina, Guarnotta; Isidori, Andrea M.; Andrea, Lania; Andrea, Lenzi; Fabio Lo Calzo, ; Pasquale, Malandrino; Erika, Messina; Roberta, Modica; Giovanna, Muscogiuri; Genoveffa, Pizza; Riccardo, Pofi; Puliani, Giulia; Carmen, Rainone; Paola, Razzore; Laura, Rizza; Manila, Rubino; Rosa Maria Ruggieri, ; Emilia, Sbardella; Franz, Sesti; Mary Anna Venneri, ; Giovanni, Vitale; Maria Chiara, Zatelli.. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - 12:(2021), p. 700806. [10.3389/fendo.2021.700806]
File allegati a questo prodotto
File Dimensione Formato  
Fanciulli_Commentary_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 257.06 kB
Formato Adobe PDF
257.06 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1603172
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact